Yoshimasa Aso

Evaluation of the effects of dapagliflozin, a sodium‐glucose co‐transporter‐2 inhibitor, on hepatic steatosis and fibrosis using transient elastography in patients with type 2 diabetes and non‐alcoholic fatty liver disease

Masanori Shimizu, Kunihiro Suzuki, Kanako Kato et al. · Diabetes Obesity and Metabolism · 2018 · 378 citations

Medicine, Pharmacology, Pharmacotherapy +17

Effect of an intensified multifactorial intervention on cardiovascular outcomes and mortality in type 2 diabetes (J-DOIT3): an open-label, randomised controlled trial

Kohjiro Ueki, Takayoshi Sasako, Yukiko Okazaki et al. · The Lancet Diabetes & Endocrinology · 2017 · 309 citations

Medicine, Cardiology, Internal Medicine +13

Comparison of Serum High–Molecular Weight (HMW) Adiponectin With Total Adiponectin Concentrations in Type 2 Diabetic Patients With Coronary Artery Disease Using a Novel Enzyme-Linked Immunosorbent Assay to Detect HMW Adiponectin

Yoshimasa Aso, Ruriko Yamamoto, Sadao Wakabayashi et al. · Diabetes · 2006 · 262 citations · Full text

Life Sciences, Biochemistry, Cardiology +17

Empagliflozin (an SGLT2 inhibitor), alone or in combination with linagliptin (a DPP-4 inhibitor), prevents steatohepatitis in a novel mouse model of non-alcoholic steatohepatitis and diabetes

Teruo Jojima, Takanori Tomotsune, Toshie Iijima et al. · Diabetology & Metabolic Syndrome · 2016 · 200 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +14

Retinol Binding Protein-4 Levels and Clinical Features of Type 2 Diabetes Patients

Kohzo Takebayashi, Mariko Suetsugu, Sadao Wakabayashi et al. · The Journal of Clinical Endocrinology & Metabolism · 2007 · 196 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +16